ArticlebioRxiv : the preprint server for biology2020
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.
Antonio E Muruato, Camila R Fontes-Garfias, Ping Ren, Mariano A Garcia-Blanco, Vineet D Menachery, Xuping Xie, Pei-Yong Shi
Open access · greenAbstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 49 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
7 authors at 2 institutions in 2 countries.
Antonio E MuruatoDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Camila R Fontes-GarfiasDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Ping RenDepartment of Pathology, University of Texas Medical Branch, Galveston TX, USA.
Mariano A Garcia-BlancoDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Xuping XieDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
The University of Texas Medical Branch at Galveston · USDuke-NUS Medical School · SG
Funding
UTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0MProject 4 - Influenza - UABU19AI142759 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WHITLEY, RICHARD J. · 2019 to 2023
$37.5MUnlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HEISE, MARK T · 2012 to 2021
$36.6MWorld Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5MUTMB Clinical and Translational Science AwardTL1TR001440 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HOMMEL, JONATHAN DEAN · 2015 to 2024
$3.4MRegulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1MConsequences and mechanism of aberrant splicing in African American prostate cancer disparitiesR01CA204806 · NCI · GEORGE WASHINGTON UNIVERSITY · PI GARCIA-BLANCO, MARIANO A., LEE, NORMAN H · 2017 to 2021
$1.8MSystems Based Analysis of Host Factors that Contribute to Aging PathogenesisR00AG049092 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2017 to 2019
$736kDiscovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health ThreatsR43AI145617 · NIAID · PLEX PHARMACEUTICALS, INC. · PI REMACLE, ALBERT, THOTA, SAMBAIAH · 2020 to 2021
$600kNCATS NIH HHS TL1 TR001440NCATS NIH HHS UL1 TR001439NCI NIH HHS R01 CA204806NIAID NIH HHS R01 AI134907NIAID NIH HHS R24 AI120942NIAID NIH HHS R43 AI145617NIAID NIH HHS U19 AI100625NIAID NIH HHS U19 AI142759NIA NIH HHS R00 AG049092
6 · The paper itselfAbstract
Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. Our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.
Indexed as
coronavirusCOVID-19diagnosisSARS-CoVSARS-CoV-2vaccine
Identifiers
PMID32511386
PMCPMC7263515
OpenAlexW3027117830
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390